PCOS
Hyperandrogenism with ovulatory dysfunction
Also searched as Hyperandrogenism with ovulatory dysfunction.
Two of its drivers feed each other: insulin resistance raises androgens, and androgens worsen insulin resistance. That is why the insulin lane above it is the one most worth pulling — it breaks the loop at the point you can reach.
In depth
Polycystic ovary syndrome — chronic ovulatory dysfunction with an excess of androgens, usually alongside insulin resistance.
What drives it
Insulin sensitivity reduces it.
Insulin resistance with compensatory hyperinsulinemia is present in 65-95% of women with PCOS and is considered a major driver of its pathophysiology — it participates directly in the development of hyperandrogenemia and reproductive dysfunction, and insulin-sensitizing treatment is an established therapeutic route. PMC9832677
Testosterone increases it.
Hyperandrogenism is one of the defining features of the syndrome: PCOS is characterized by an overabundance of androgens alongside chronic ovulatory dysfunction, and hyperandrogenemia in turn aggravates insulin resistance — the two reinforce each other. PMC9832677
Supports weight management increases it.
Obesity aggravates the insulin resistance that drives the syndrome, and lifestyle improvement is first-line in every current treatment framework (PMC9832677, PMC9030414). PCOS affects 6-20% of women of reproductive age. PMC9832677
Fasting insulin increases it.
Named across five reviews of the cardiovascular-renal-hepatic-metabolic syndrome as part of the shared mechanism set: ectopic fat accumulation triggered by metabolic reprogramming, oxidative stress and inflammation induced by energy overload, modified lipids, UREMIC toxins, and senescence, as well as insulin resistance pathways activated by pro-inflammatory factors and lipotoxic products, collectively exacerbate simultaneous hepatic and renal injury. doi 10.1038/s41581-026-01066-0 · PMC11725408
Blocks the hormone that shrinks follicles increases it.
Named across five reviews of the cardiovascular-renal-hepatic-metabolic syndrome as part of the shared mechanism set: ectopic fat accumulation triggered by metabolic reprogramming, oxidative stress and inflammation induced by energy overload, modified lipids, UREMIC toxins, and senescence, as well as insulin resistance pathways activated by pro-inflammatory factors and lipotoxic products, collectively exacerbate simultaneous hepatic and renal injury. doi 10.1038/s41581-026-01066-0 · PMC11725408
Hormone-binding protein reduces it.
SHBG binds circulating androgen; low SHBG raises free testosterone and is a consistent feature of PCOS. PMC9967593
Reproductive axis reduces it.
Named across five reviews of the cardiovascular-renal-hepatic-metabolic syndrome as part of the shared mechanism set: ectopic fat accumulation triggered by metabolic reprogramming, oxidative stress and inflammation induced by energy overload, modified lipids, UREMIC toxins, and senescence, as well as insulin resistance pathways activated by pro-inflammatory factors and lipotoxic products, collectively exacerbate simultaneous hepatic and renal injury. doi 10.1038/s41581-026-01066-0 · PMC11725408
Calms body-wide inflammation increases it.
heart, kidney, liver, and metabolic diseases share interlinked pathological mechanisms, including inflammation, oxidative stress, insulin resistance, and endothelial health issues. doi 10.1038/s41581-026-01066-0 · PMC11725408
Gut barrier reduces it.
Named across five reviews of the cardiovascular-renal-hepatic-metabolic syndrome as part of the shared mechanism set: ectopic fat accumulation triggered by metabolic reprogramming, oxidative stress and inflammation induced by energy overload, modified lipids, UREMIC toxins, and senescence, as well as insulin resistance pathways activated by pro-inflammatory factors and lipotoxic products, collectively exacerbate simultaneous hepatic and renal injury. doi 10.1038/s41581-026-01066-0 · PMC11725408
Lowers cholesterol reduces it.
Named across five reviews of the cardiovascular-renal-hepatic-metabolic syndrome as part of the shared mechanism set: ectopic fat accumulation triggered by metabolic reprogramming, oxidative stress and inflammation induced by energy overload, modified lipids, UREMIC toxins, and senescence, as well as insulin resistance pathways activated by pro-inflammatory factors and lipotoxic products, collectively exacerbate simultaneous hepatic and renal injury. doi 10.1038/s41581-026-01066-0 · PMC11725408
Liver reduces it.
An estimated 50-70 percent of obese women with PCOS have NAFLD, compared to 20-30 percent of obese women without PCOS. And the arrow is explicitly bidirectional in the source: while it is recognized that PCOS may contribute to hepatic dysfunction, there is also evidence that the liver may contribute to the features of PCOS. One arrow is drawn, though the relationship runs both ways. doi 10.1038/s41581-026-01066-0 · PMC11725408
Clears liver fat increases it.
Named across five reviews of the cardiovascular-renal-hepatic-metabolic syndrome as part of the shared mechanism set: ectopic fat accumulation triggered by metabolic reprogramming, oxidative stress and inflammation induced by energy overload, modified lipids, UREMIC toxins, and senescence, as well as insulin resistance pathways activated by pro-inflammatory factors and lipotoxic products, collectively exacerbate simultaneous hepatic and renal injury. doi 10.1038/s41581-026-01066-0 · PMC11725408
Estrogen balance increases it.
Named across five reviews of the cardiovascular-renal-hepatic-metabolic syndrome as part of the shared mechanism set: ectopic fat accumulation triggered by metabolic reprogramming, oxidative stress and inflammation induced by energy overload, modified lipids, UREMIC toxins, and senescence, as well as insulin resistance pathways activated by pro-inflammatory factors and lipotoxic products, collectively exacerbate simultaneous hepatic and renal injury. doi 10.1038/s41581-026-01066-0 · PMC11725408
Lipid synthesis switch increases it.
SREBP-1c drives de novo lipogenesis; its activation accompanies the insulin-resistant, lipogenic state of PCOS. PMC7005133
What it drives
It reduces Liver.
The source is explicitly bidirectional: while it is recognized that PCOS may contribute to hepatic dysfunction, there is also evidence that the liver may contribute to the features of PCOS. An estimated 50-70 percent of obese women with PCOS have NAFLD, compared to 20-30 percent of obese women without PCOS - roughly a doubling. A rat model shows the mechanism: insulin and hCG treatment induced imbalance between DE novo lipogenesis and mitochondrial beta-oxidation via the PPARa/b-SREBP1/2-ACC1 axis, resulting in varying degrees of hepatic steatosis. Species: that mechanistic arm is rat. PMC11764088
It increases Type 2 diabetes.
10.3390/biomedicines10061455 — PCOS carries markedly increased type 2 diabetes risk. doi 10.3390/biomedicines10061455
It reduces Heart & blood pressure.
10.4274/tjod.galenos.2025.04680 — Increased cardiovascular risk is a recognized PCOS consequence. doi 10.4274/tjod.galenos.2025.04680
It increases Clears liver fat.
10.2147/DMSO.S362424 — 50-70 percent of obese women with PCOS have NAFLD versus 20-30 percent without. doi 10.2147/DMSO.S362424
It reduces Women's hormone balance.
NBK459251 — Anovulation and menstrual dysfunction are the defining clinical features.
It reduces Mood.
10.1093/humrep/dex044 — PCOS carries documented psychological burden. This link rests on the reviews of this outcome as a whole, and no effect size specific to it has been reported. doi 10.1093/humrep/dex044
It reduces Hair.
10.1371/journal.pone.0223329 — Hirsutism and androgenic alopecia follow from hyperandrogenism. doi 10.1371/journal.pone.0223329
It reduces Female fertility.
The central finding is that reactive oxygen species ARE required, not merely harmful: ROS in the ovary regulate ovarian steroid hormone production, follicle synthesis, maturation, ovulation, and tubal function. ROS and antioxidant levels regulate the microenvironment of the follicular fluid, which determines which follicle becomes dominant. ROS can trigger ovulation in mature GRAAF follicles, and any change in this ROS level can disrupt ovulation. So an antioxidant claim here cuts both ways - the requirement is redox homeostasis, not suppression. Excess oxidative stress damages the oocyte through mitochondrial dysfunction, follicular atresia, meiotic errors, DNA damage and telomere shortening; too little disrupts the ovulatory trigger itself. Scale: infertility affects approximately 10-15 percent of couples, with nearly half the cases attributed to female reproductive dysfunction. doi 10.3390/antiox12081490 · PMID 40712896 · PMC10666387
It increases Clear skin.
10.7759/cureus.98103 — Drawn from reviews of neighboring outcomes rather than from studies of this outcome itself, which is weaker evidence, and the map marks it so. doi 10.7759/cureus.98103
Blends that modulate it
Each blend page names this pathway and carries the study behind its claim.
See it on the map
Open the causal map to follow this pathway upstream and downstream, arrow by arrow, each with its study.